Company Data

Medivation Inc.

Ticker
MDVN
Current Price
$81.44
Market Cap
$3.8B
Price Target
Refer to Report
Volume
2.5M
52wk Range
$26.41 - $81.48
Advanced Market Data

Overview

Medivation Inc was formed in Delaware in October 1995. The Company is a biopharmaceutical company engaged in the rapid development of novel small molecule drugs to treat diseases for which there are limited treatment options. Together with its collaboration partner Astellas Pharma Inc., or Astellas, the Company is developing XTANDI enzalutamide capsules. Together with Astellas, it is also conducting multiple trials of enzalutamide in earlier prostate cancer disease states, including the Phase 3 PREVAIL trial in patients with mCRPC who have not received chemotherapy, or pre-chemotherapy mCRPC patients, and in patients with breast cancer. Based on the positive results of the AFFIRM trial, the Company has exercised its right under its collaboration agreement with Astellas to co-promote XTANDI in the U.S., should it receive marketing approval.

Research Reports

    Inbox Intel from Channelchek.

    Informed investors make more money. And it’s all about timing. Get it when it happens.

    By clicking submit you are agreeing to the Terms of Use and Privacy Policy
    © 2018-2023 Noble Financial Group, Inc. All Rights Reserved. Channelchek is provided at no cost to be used for information purposes only and not as investment advisement.